Animal Parasiticides Market by Product Type (Endoparasiticides, Ectoparasiticides, and Endectocides), by Animal Type (Cats, Dogs, Pigs, Cattle, Goats, Sheep, and Others), and by End-User (R&D Facilities, Farms, and Veterinary Clinics)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020–2029

                                          
<
Abstract


The report covers a forecast and an analysis of the animal parasiticides market on a global and regional level. The study provides historical data from 2015 to 2019 along with a forecast from 2020 to 2029 based on revenue (USD Billion). The study includes drivers and restraints of the animal parasiticides market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the animal parasiticides market on a global and regional level.

In order to give the users of this report a comprehensive view of the animal parasiticides market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the animal parasiticides market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the animal parasiticides market on a global and regional basis.

The study provides a decisive view of the animal parasiticides market by segmenting the market based on product type, animal type, end-user, and region. By product type, the animal parasiticides market is segmented into endoparasiticides, ectoparasiticides, and endectocides. The endoparasiticides are sub-segmented into injectables, oral solids, feed additives, oral liquids, and others. The ectoparasiticides are sub-segmented into sprays, spot-on and pour-on, dips, collars, oral tablets, ear tags, and others. The animal type segment is divided into cats, dogs, pigs, cattle, goats, sheep, and others. The end-user segment is fragmented into R&D facilities, farms, and veterinary clinics.

Coccidiosis, a common cause of scours (diarrhea) in lambs and calves that is highly prevalent on cattle and sheep farms, is caused by protozoan parasites called Eimeria that multiply in the intestinal wall, transmitted from animal to animal by the fecal-oral route. Clinical signs include painful scours with or without blood, and decreased appetite and depression, which may progress to dehydration and weight loss. Coccidiosis primarily affects young animals; calves and lambs as young as three to four weeks of age may be affected.

Coccidiosis causes significant economic loss to farmers and producers due to reduced feed conversion, reduced growth rates, reduced performance or death, and by increased susceptibility to other infections, such as intestinal disease or Bovine Respiratory Disease.

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Germany, France, UK, China, Japan, India, and Brazil.

Some players of the global animal parasiticides market are Eli Lilly and Company, Sanofi, Virbac, Zoetis, Inc., Ceva Sante Animale, Vetoquinol S.A., Merck and Co., Inc., Perrigo Company, Boehringer Ingelheim, and Bayer AG, among others.

This report segments the global animal parasiticides market as follows:

Global Animal Parasiticides Market: By Product Type

Endoparasiticides

  
Injectables
  
Oral Solids
  
Feed Additives
  
Oral Liquids
  
Others

Ectoparasiticides

  
Sprays
  
Spot-On and Pour-On
  
Dips
  
Collars
  
Oral Tablets
  
Ear Tags
  
Others

Endectocides

Global Animal Parasiticides Market: By Animal Type

  
Cats
  
Dogs
  
Pigs
  
Cattle
  
Goats
  
Sheep
  
Others

Global Animal Parasiticides Market: By End-User

  
R&D Facilities
  
Farms
  
Veterinary Clinics

Global Animal Parasiticides Market: By Region

  
North America
  
Europe
  
Asia Pacific
  
Latin America
  
Middle East and Africa

In Aug 2020, Merck Animal Health Completed the Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio. The acquisition Broadens Merck Animal Healths Position with Enhanced Parasite Protection in Calves and Lambs. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its previously announced acquisition of the worldwide rights to VECOXAN® (diclazuril), an oral suspension for the prevention of coccidiosis in calves and lambs, from Elanco Animal Health.

VECOXAN is efficacious, in lambs, against the prevention of coccidiosis caused by Eimeria crandallis and Eimeria ovinoidalis, and in calves, against coccidiosis caused by Eimeria bovis and Eimeria zuernii. VECOXAN is available in Europe, South Africa, South Korea and Japan.

Coccidiosis causes significant economic loss to farmers and producers due to reduced feed conversion, reduced growth rates, reduced performance or death, and by increased susceptibility to other infections, such as intestinal disease or Bovine Respiratory Disease.

Elanco Animal Health Inc. agreed to sell the worldwide rights for Vecoxan to Merck & Co. Inc. unit Merck Animal Health for $55 million in an all-cash deal. Elanco is divesting the rights in a bid to address antitrust concerns regarding its $7.6 billion acquisition of Bayers animal health business, which is expected to close in mid-2020.

The Vecoxan deal brings the total divestitures between $120 million and $140 million in revenue, which Elanco previously stated it would need to divest across both organizations to achieve any required clearances globally. In total, Elanco has generated about $425 million in pretax proceeds from the divestitures, and the company plans to use these funds to pay down debt associated with the Bayer animal health deal.

Elanco has received antitrust clearance for the acquisition in China, Turkey and Ukraine. The company noted that it is in advanced discussions with the required regulatory authorities, which are progressing as expected. Vecoxan joins Elancos previously announced Osurnia® and Capstar® divestitures, and divestiture of European Economic Area and U.K. rights for Drontal® and Profender® from the Bayer portfolio.